Oxygenta [OXYGENTAPH] vs Sun Pharma Advanced [SPARC] Detailed Stock Comparison
Oxygenta
BSE
Loading...
Sun Pharma Advanced
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Oxygenta wins in 12 metrics, Sun Pharma Advanced wins in 4 metrics, with 0 ties. Oxygenta appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Oxygenta | Sun Pharma Advanced | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 444.32 | -13.92 | Sun Pharma Advanced |
| Price-to-Book Ratio | N/A | -21.95 | N/A |
| Debt-to-Equity Ratio | -2.43 | -1.24 | Oxygenta |
| PEG Ratio | N/A | 0.30 | N/A |
| EV/EBITDA | -28.18 | -17.77 | Oxygenta |
| Profit Margin (TTM) | -13.45% | -53.22% | Oxygenta |
| Operating Margin (TTM) | -50.72% | -568.05% | Oxygenta |
| Return on Equity | 40.16% | 157.88% | Sun Pharma Advanced |
| Return on Assets (TTM) | -12.44% | -102.08% | Oxygenta |
| Free Cash Flow (TTM) | $-87.89M | $-3.71B | Oxygenta |
| 1-Year Return | 99.93% | -34.90% | Oxygenta |
| Price-to-Sales Ratio (TTM) | 2.69 | 73.95 | Oxygenta |
| Enterprise Value | $3.70B | $50.39B | Sun Pharma Advanced |
| EV/Revenue Ratio | 3.31 | 78.01 | Oxygenta |
| Gross Profit Margin (TTM) | 4.52% | -10.68% | Oxygenta |
| Revenue per Share (TTM) | $31 | $2 | Oxygenta |
| Earnings per Share (Diluted) | $-2.86 | $-9.19 | Oxygenta |
| Beta (Stock Volatility) | 0.56 | 0.31 | Sun Pharma Advanced |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Oxygenta vs Sun Pharma Advanced Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Oxygenta | -0.12% | -9.18% | -27.15% | -10.28% | -0.25% | -5.93% |
| Sun Pharma Advanced | 0.71% | 3.43% | -9.83% | -12.50% | 12.07% | -27.72% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Oxygenta | 99.93% | 193.27% | 211.39% | 211.39% | 211.39% | 211.39% |
| Sun Pharma Advanced | -34.90% | -37.57% | -23.72% | -61.16% | 57.59% | -50.10% |
Performance & Financial Health Analysis: Oxygenta vs Sun Pharma Advanced
| Metric | OXYGENTAPH | SPARC |
|---|---|---|
| Market Information | ||
| Market Cap | ₹3.01B | ₹47.77B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 8,480 | 286,237 |
| 90 Day Avg. Volume | 4,887 | 355,426 |
| Last Close | ₹80.55 | ₹146.08 |
| 52 Week Range | ₹35.80 - ₹133.50 | ₹109.30 - ₹241.00 |
| % from 52W High | -39.66% | -39.39% |
| All-Time High | ₹133.50 (Jun 09, 2025) | ₹875.00 (Apr 24, 2006) |
| % from All-Time High | -39.66% | -83.31% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.20% | -0.43% |
| Quarterly Earnings Growth | 3.69% | -0.43% |
| Financial Health | ||
| Profit Margin (TTM) | -0.13% | -0.53% |
| Operating Margin (TTM) | -0.51% | -5.68% |
| Return on Equity (TTM) | 0.40% | 1.58% |
| Debt to Equity (MRQ) | -2.43 | -1.24 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹-7.15 | ₹-6.69 |
| Cash per Share (MRQ) | ₹0.03 | ₹0.06 |
| Operating Cash Flow (TTM) | ₹-89,042,000 | ₹-3,484,287,000 |
| Levered Free Cash Flow (TTM) | ₹-102,983,000 | ₹-3,425,094,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Oxygenta vs Sun Pharma Advanced
| Metric | OXYGENTAPH | SPARC |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 444.32 | -13.92 |
| Forward P/E | N/A | 2.65 |
| PEG Ratio | N/A | 0.30 |
| Price to Sales (TTM) | 2.69 | 73.95 |
| Price to Book (MRQ) | N/A | -21.95 |
| Market Capitalization | ||
| Market Capitalization | ₹3.01B | ₹47.77B |
| Enterprise Value | ₹3.70B | ₹50.39B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.31 | 78.01 |
| Enterprise to EBITDA | -28.18 | -17.77 |
| Risk & Other Metrics | ||
| Beta | 0.56 | 0.31 |
| Book Value per Share (MRQ) | ₹-7.15 | ₹-6.69 |
Financial Statements Comparison: Oxygenta vs Sun Pharma Advanced
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | OXYGENTAPH | SPARC |
|---|---|---|
| Revenue/Sales | ₹494.67M | ₹96.40M |
| Cost of Goods Sold | ₹472.30M | ₹106.70M |
| Gross Profit | ₹22.37M | ₹-10.30M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹-14.00M | ₹-547.60M |
| EBITDA | ₹-13.51M | ₹-429.40M |
| Pre-Tax Income | ₹-37.99M | ₹-518.10M |
| Income Tax | ₹-16.46M | ₹600,000 |
| Net Income (Profit) | ₹-21.53M | ₹-518.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | OXYGENTAPH | SPARC |
|---|---|---|
| Cash & Equivalents | ₹17,000 | ₹19.64M |
| Total Current Assets | ₹309.43M | ₹261.97M |
| Total Current Liabilities | ₹858.47M | ₹3.74B |
| Long-Term Debt | ₹215.22M | ₹1.07B |
| Total Shareholders Equity | ₹-256.41M | ₹-2.17B |
| Retained Earnings | N/A | ₹-23.22B |
| Property, Plant & Equipment | ₹368.30M | ₹178.02M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | OXYGENTAPH | SPARC |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | OXYGENTAPH | SPARC |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 8,480 | 286,237 |
| Average Daily Volume (90 Day) | 4,887 | 355,426 |
| Shares Outstanding | 36.98M | 324.52M |
| Float Shares | 2.30M | 91.74M |
| % Held by Insiders | 0.79% | 0.73% |
| % Held by Institutions | 0.00% | 0.02% |
Dividend Analysis & Yield Comparison: Oxygenta vs Sun Pharma Advanced
| Metric | OXYGENTAPH | SPARC |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |